首页> 美国卫生研究院文献>other >Gene Therapy for MERTK-Associated Retinal Degenerations
【2h】

Gene Therapy for MERTK-Associated Retinal Degenerations

机译:MERTK相关视网膜变性的基因治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

MERTK-associated retinal degenerations are thought to have defects in phagocytosis of shed outer segment membranes by the retinal pigment epithelium (RPE), as do the rodent models of these diseases. We have subretinally injected an RPE-specific AAV2 vector, AAV2-VMD2-hMERTK, to determine whether this would provide long-term photoreceptor rescue in the RCS rat, which it did for up to 6.5 months, the longest time point examined. Moreover, we found phagosomes in the RPE in the rescued regions of RCS retinas soon after the onset of light. The same vector also had a major protective effect in Mertk-null mice, with a concomitant increase in ERG response amplitudes in the vector-injected eyes. These findings suggest that planned clinical trials with this vector will have a favorable outcome.
机译:认为与MERTK相关的视网膜变性在视网膜色素上皮(RPE)吞噬脱落的外节膜上具有缺陷,这些疾病的啮齿动物模型也是如此。我们已经在视网膜下注射了RPE特异的AAV2载体AAV2-VMD2-hMERTK,以确定它是否能够在RCS大鼠中提供长期的感光受体拯救,该过程可以长达6.5个月,这是检查的最长时间点。此外,我们在光照开始后不久就在RCS视网膜受救区域的RPE中发现了吞噬体。相同的载体在Mertk-null小鼠中也具有主要的保护作用,伴随着载体注射的眼睛的ERG反应幅度随之增加。这些发现表明,计划用该载体进行的临床试验将有良好的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号